(Albany, US) DelveInsight has launched a new report on “Meningioma Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Meningioma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Meningioma , historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
Request for free sample report: https://www.delveinsight.com/sample-request/meningioma-market
Scope of the Report:
Meningiomas are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. The other two layers of the meninges are the dura mater and pia mater. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening. Other forms of meningioma may be more aggressive. Most patients develop a single meningioma; however, some patients may develop several tumors growing simultaneously in other locations of the brain or spinal cord.
Often, meningiomas cause no symptoms and require no immediate treatment. But the growth of benign meningiomas can cause serious problems. In some cases, such growth can be fatal. Some meningiomas are classified as atypical. These are not considered either benign or malignant (cancerous). But they may become malignant. A small number of meningiomas are cancerous. They tend to grow quickly. They also can spread to other parts of the brain and beyond, often to the lungs.
Risk factors for a meningioma include radiation treatment, female hormones, an inherited nervous system disorder, or obesity.
The WHO classification of brain tumors is the most widely utilized tool in grading tumor types. The WHO classification scheme recognizes 15 variations of meningiomas according to their cell type as seen under a microscope. These variations are called meningioma subtypes – the technical term for these cell variations is histological subtypes. These histological subtypes are organized into three grades that generally reflects the rate of growth and the likelihood of recurrence based on cytological features.
Atypical meningiomas (WHO grade II, which account for 18% of meningioma cases) exhibit increased tissue and cell abnormalities. These tumors grow at a faster rate than benign meningiomas and are often characterized by brain invasion. Atypical meningiomas have a higher likelihood of recurrence than benign meningiomas (WHO grade I).
Malignant meningiomas (WHO grade III) show increased cellular abnormalities and grow at a faster rate than benign and atypical meningiomas. Malignant meningiomas are the most likely to invade the brain and recur more frequently than the other two subtypes.
It can be difficult to diagnose meningiomas for several reasons. Because the majority of meningiomas are slow-growing tumors and primarily affect adults, symptoms may be so subtle that the patient and/or doctor may attribute them to the normal signs of aging. Adding to the confusion is that some of the symptoms associated with meningiomas can also be due to other medical conditions. Misdiagnosis is not uncommon and, may take several years for correct diagnosis.
Some of the companies are:
Drugs covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Meningioma
3. Competitive Intelligence Analysis for Meningioma
4. Meningioma : Market Overview at a Glance
4.1. Meningioma Total Market Share (%) Distribution in 2017
4.2. Meningioma Total Market Share (%) Distribution in 2030
5. Meningioma : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Meningioma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Meningioma Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Meningioma Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Meningioma Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Meningioma Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Meningioma Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Meningioma Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Meningioma Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Meningioma Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Meningioma Treatment and Management
8.2. Meningioma Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Meningioma Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Meningioma : Seven Major Market Analysis
13.1. Key Findings
13.2. Meningioma Market Size in 7MM
13.3. Meningioma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Meningioma Total Market Size in the United States
15.1.2. Meningioma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Meningioma Total Market Size in Germany
15.3.2. Meningioma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Meningioma Total Market Size in France
15.4.2. Meningioma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Meningioma Total Market Size in Italy
15.5.2. Meningioma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Meningioma Total Market Size in Spain
15.6.2. Meningioma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Meningioma Total Market Size in the United Kingdom
15.7.2. Meningioma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Meningioma Total Market Size in Japan
15.8.3. Meningioma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Meningioma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/meningioma-market?utm_source=Pressrelease&utm_medium=Pressrelease&utm_campaign=Pressrelease